%0 Journal Article
%T Nivolumab for the treatment of Japanese patients with advanced metastatic non-small cell lung cancer: a review of clinical trial evidence for efficacy and safety
%A Toyoaki Hida
%J Archive of "Therapeutic Advances in Respiratory Disease".
%D 2018
%R 10.1177/1753466618801167
%X Programmed cell death (PD)-1 immune checkpoint inhibitors have emerged as promising options for the treatment of multiple cancer types. Nivolumab is a fully human immunoglobulin G4 monoclonal antibody, which inhibits the PD-1 receptor and has been approved in the United States, Europe, and Asia for the treatment of advanced NSCLC. This review focuses on nivolumab¡¯s efficacy and safety in the treatment of NSCLC patients in Japan
%K Nivolumab
%K Non-small cell lung cancer
%K PD-1 inhibitor
%K Japanese
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6156204/